Journal ArticleDOI
Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
Reads0
Chats0
TLDR
The role of immunohistochemistry for EGFR expression continues to be a poor predictor of patients who may benefit from cetuximab, which has shown considerable activity-both as monotherapy and in combination with chemotherapy-in the treatment of metastatic colorectal cancer that is resistant to chemotherapy.About:
This article is published in Clinical Therapeutics.The article was published on 2005-06-01. It has received 225 citations till now. The article focuses on the topics: Cetuximab & Head and neck cancer.read more
Citations
More filters
Journal Article
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Journal ArticleDOI
Au nanoparticles target cancer
TL;DR: This work discusses recent advances in the study and use of selectively targeted Au nanospheres in cancer photodiagnostics and photothermal therapy, and the use of Au nanorods and silica-Au core-shell nanoparticles for in vivo cancer detection and therapy.
Journal ArticleDOI
Comparing antibody and small-molecule therapies for cancer
Kohzoh Imai,Akinori Takaoka +1 more
TL;DR: The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-molecule compounds have been approved for cancer treatment.
Journal ArticleDOI
Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
TL;DR: A review of the biology of EGFR, preclinical and clinical development of inhibitors, and molecular mechanisms that underlie the development of treatment resistance is provided in this article. But, as is common in cancer therapy, challenges with respect to treatment resistance emerge over time.
Journal ArticleDOI
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
TL;DR: The role of EGfr in cancer, different types of EGFR inhibitors, preclinical and clinical status of EG FR inhibitors as well as summarized the recent efforts made in the field of molecular EGFR targeting are outlined.
References
More filters
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more
TL;DR: The derivation of a number of tissue culture cell lines which secrete anti-sheep red blood cell (SRBC) antibodies is described here, made by fusion of a mouse myeloma and mouse spleen cells from an immunised donor.
Book
Cancer : Principles and Practice of Oncology
TL;DR: Part I: Molecular Biology of Cancer Molecular Methods in Oncology Section 1. Amplification Techniques Section 2. RNA Interference Section 3. cDNA arrays Section 4. Tissue arrays Section 5. Cytogenetics Section 6. Bioinformatics Genomics and Proteomics Molecular Targets in oncology.
Journal ArticleDOI
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
David Cunningham,Yves Humblet,Salvatore Siena,David Khayat,Harry Bleiberg,Armando Santoro,D. Bets,M. Mueser,Andreas Harstrick,Chris Verslype,Ian Chau,Eric Van Cutsem +11 more
TL;DR: Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer.
Journal ArticleDOI
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont,A. Figer,M. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,H. Cortes-Funes,Andrés Cervantes,Gilles Freyer,Demetris Papamichael,N. Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Related Papers (5)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more